Cingulate Inc. (CING) stock
CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
$4.64+0.08 (+1.75%)
Close on Nov 11, 2026Market cap $67.47MP/E –Yield –
Cingulate r&d expenses
Research and development expenses are spending on new products and technology.
Cingulate's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.52M. For fiscal 2025 it was $9.77M, up 3.5% from the year before. The highest annual figure on record is $15.49M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.77M | +3.5% |
| FY2024 | Dec 31, 2024 | $9.45M | -39.0% |
| FY2023 | Dec 31, 2023 | $15.49M | +72.2% |
| FY2022 | Dec 31, 2022 | $9.00M | +7.0% |
| FY2021 | Dec 31, 2021 | $8.41M | +65.1% |
| FY2020 | Dec 31, 2020 | $5.09M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.49M | -45.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.18M | -1.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.00M | -53.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.85M | +57.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.70M | -45.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.22M | -43.4% |
| Q4 FY2024 | Dec 31, 2024 | $4.33M | -2.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.81M | -15.1% |
| Q4 FY2023 | Dec 31, 2023 | $4.98M | +158.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.92M | +84.8% |
| Q2 FY2023 | Jun 30, 2023 | $4.46M | +104.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.13M | -22.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.93M | +52.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.12M | -63.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.18M | +174.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.76M | +391.1% |
| Q4 FY2021 | Dec 31, 2021 | $1.26M | – |
| Q3 FY2021 | Sep 30, 2021 | $5.79M | – |
| Q2 FY2021 | Jun 30, 2021 | $793.59K | – |
| Q1 FY2021 | Mar 31, 2021 | $562.52K | – |
See a number that looks wrong?